Riluzole 50 mg (part b) (DrugBank: Riluzole)
8 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
2 | 筋萎縮性側索硬化症 | 1 |
3 | 脊髄性筋萎縮症 | 0 |
5 | 進行性核上性麻痺 | 0 |
8 | ハンチントン病 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
17 | 多系統萎縮症 | 0 |
18 | 脊髄小脳変性症(多系統萎縮症を除く。) | 0 |
206 | 脆弱X症候群 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01378676 (ClinicalTrials.gov) | June 2011 | 20/6/2011 | A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Placebo (Part A);Drug: CK-2017357 (Part A);Drug: Riluzole 50 MG (Part B);Drug: Placebo (Part B);Drug: CK-2017357 (Part B) | Cytokinetics | NULL | Completed | 18 Years | N/A | All | 49 | Phase 2 | United States |